151 related articles for article (PubMed ID: 33058520)
1. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.
Battaglia S; Maguire O; Thorne JL; Hornung LB; Doig CL; Liu S; Sucheston LE; Bianchi A; Khanim FL; Gommersall LM; Coulter HS; Rakha S; Giddings I; O'Neill LP; Cooper CS; McCabe CJ; Bunce CM; Campbell MJ
Carcinogenesis; 2010 Sep; 31(9):1650-60. PubMed ID: 20466759
[TBL] [Abstract][Full Text] [Related]
4. Determination of TMPRSS2-ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
6. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
7. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
8. The Molecular Taxonomy of Primary Prostate Cancer.
Cancer Genome Atlas Research Network
Cell; 2015 Nov; 163(4):1011-25. PubMed ID: 26544944
[TBL] [Abstract][Full Text] [Related]
9. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer.
Zhou J; Lai Y; Peng S; Tang C; Chen Y; Li L; Huang H; Guo Z
Front Oncol; 2022; 12():957404. PubMed ID: 36119488
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes of Prostate Cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract][Full Text] [Related]
12. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
13. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
[TBL] [Abstract][Full Text] [Related]
15. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
17. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
[TBL] [Abstract][Full Text] [Related]
19. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
20. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
